Moderna aims to deliver 1 billion more vaccine doses to low-income countries in 2022

(Reuters) -Moderna Inc said on Friday it aims to deliver one billion doses of its COVID-19 vaccine to low-income countries in 2022, in addition to the doses it has already committed to the global vaccine-sharing platform COVAX.

These vaccines will be part of the 2-3 billion doses the company had forecast to produce next year.

“To date, more than 250 million people have been vaccinated globally with the Moderna COVID-19 vaccine. However, we recognize that access to vaccines continues to be a challenge in many parts of the world,” Chief Executive Officer Stéphane Bancel said in a letter posted on the company’s website.

Moderna on Thursday announced plans to invest up to $500 million to build a factory in Africa to make up to 500 million doses of mRNA vaccines each year, including its COVID-19 shot.

The company had committed in May to supply up to 500 million doses of its COVID-19 vaccine to the COVAX facility from the fourth quarter of 2021 through 2022.

“We are committed to doubling our manufacturing and expanding supply even further until our vaccine is no longer needed in low-income countries,” Bancel said.

(Reporting by Manojna Maddipatla in Bengaluru; Editing by Saumyadeb Chakrabarty and Vinay Dwivedi)

WHO’s pandemic project faces cash crunch amid vaccine, oxygen shortages

By Francesco Guarascio

BRUSSELS (Reuters) – The World Health Organization (WHO) is seeking $11.5 billion in urgent funding to fight the more infectious Delta variant of the coronavirus, a draft report seen by Reuters shows, amid worries wealthy nations are partly bypassing its COVID-19 programs.

A large portion of the cash being requested from the WHO’s partners is needed to buy tests, oxygen and face masks in poorer nations, says the document which is expected to be released this week. And a quarter of it would be to buy hundreds of millions of vaccines for them that would otherwise go elsewhere.

The paper, still subject to changes, outlines the results and financial needs of the Access to COVID-19 Tools Accelerator (ACT-A), the program co-led by the WHO to distribute fairly COVID-19 vaccines, drugs and tests across the world.

The program, set up at the start of the pandemic, remains vastly underfunded, and its coordinators are now acknowledging it will remain so as many governments look to address global COVID needs “differently,” an ACT-A official told Reuters, speaking on condition of anonymity.

As a result, it has cut by nearly $5 billion its total request for funds, the document shows. But it still needs $16.8 billion, almost as much as what has been raised so far, and $7.7 billion is required urgently.

The document also calls for a further $3.8 billion, on top of the $7.7 billion, to take up options for 760 million doses of COVID-19 vaccines that would be delivered next year.

“These options to buy need to be exercised in the coming months or vaccine doses will be lost,” the document warns.

WHO Director-General Tedros Adhanom Ghebreyesus last week said that $7.7 billion were urgently needed, but did not give a breakdown of planned spending, and did not say how much extra money was needed for vaccines.

The WHO was not immediately available to comment.

The latest cash crunch will underscore concerns about the long-term future of the program, which has struggled to secure supplies and equipment to tame a pandemic that has killed more than 4.2 million.

The vaccine portion of the project, called COVAX, is increasingly reliant on donations from wealthy nations, rather than its own supplies, after key manufacturer India restricted exports of shots to boost domestic vaccinations.

But the United States, European Union and Japan have also donated vaccines directly to countries as part of their vaccine diplomacy drives. Japan has also said it’s a quicker process than going through COVAX.

Some countries have provided equipment directly to others too. Last month, Australia said it would donate oxygen-related equipment, antigen test-kits as well as vaccines to Indonesia.

The plea for cash comes as a review of the ACT-A gets under way, with France, Germany and Canada among the countries steering the process. A report on the program’s results and shortcomings is expected in September by consultancy Dalberg Global Development Advisors, the ACT-A official said.

OXYGEN NEEDS

Among ACT-A’s immediate needs are $1.2 billion for oxygen to treat seriously ill COVID-19 patients in poorer countries where supplies are low, the report says.

Oxygen has moved up the priority list given vaccines are not available, the ACT-A official said, highlighting the repercussions from the shortage of shots as the Delta variant spreads to 132 countries.

COVAX has delivered about 180 million vaccines, far short of its 2 billion target by the end of this year.

Oxygen is needed to “control the exponential death surges caused by the Delta variant,” the document says.

Global demand for medical oxygen is currently more than a dozen times greater than before the pandemic, the document says, but many countries are struggling to access sufficient supplies.

The urgent need for the most basic treatment against COVID-19 one and a half years into the pandemic shows how little has been done to combat the virus in most of the world, the ACT-A official said, noting: “There hasn’t been much progress. What was urgent three months ago is still urgent now.”

“Inequity in access to life-saving COVID-19 tools has never been more apparent,” the document says.

In rich nations, most people have already been vaccinated, including the younger who are less at risk from COVID-19, whereas in poorer nations the most vulnerable are still waiting for a first dose and there is a lack of basic materials, such as face masks and other personal protective equipment (PPE).

“Avoidable death and unsustainable pressure on health systems is mounting in many countries due to insufficient access to oxygen and PPE,” the document says.

At least $1.7 billion are urgently needed to buy protective devices for healthcare workers in poorer nations, the document says, and another $2.4 billion are needed to boost testing in low-income countries.

(Reporting by Francesco Guarascio @fraguarascio; Editing by Josephine Mason and Mark Potter)

COVAX aims to resolve Venezuela COVID-19 vaccine roadblocks after Maduro ‘ultimatum’

CARACAS (Reuters) – The COVAX vaccine-sharing facility is aiming to overcome roadblocks to the shipment of coronavirus shots to Venezuela “as soon as possible,” a spokesman for the GAVI alliance said on Tuesday.

The comments from GAVI, the Vaccine Alliance which runs COVAX with the World Health Organization, came after President Nicolas Maduro on Sunday said he was giving the COVAX system an “ultimatum” to send doses to the crisis-stricken South American country or return the money Venezuela had already paid.

Officials from the OPEC nation said in June that several payments to cover the $120 million fee have been made, but that the final four payments have been blocked by Swiss bank UBS. Maduro’s allies have attributed that to U.S. sanctions aimed at ousting him from the presidency.

“We are working to resolve this matter as quickly as possible,” a GAVI spokesperson said.

Washington in 2019 blacklisted Venezuela’s state oil company, central bank and other government institutions, though it exempts humanitarian transactions from the sanctions.

Still, the measures have left many banks wary of processing even authorized Venezuela-related transactions.

Venezuela’s COVAX payments are not subject to any sanctions, but pose compliance problems for UBS because the government has not satisfactorily spelled out to the bank exactly what the payment is for, a person familiar with the matter said, adding that UBS will execute the transaction as soon as the open questions are clarified.

Venezuela’s information ministry did not immediately respond to a request for comment.

Several of the payments to COVAX were made by local Venezuelan banks on the government’s behalf, Reuters reported last month.

Venezuela has received 3.5 million vaccine doses from allies Russia and China, and is also conducting trials for Cuba’s Abdala vaccine.

(Reporting by Mayela Armas and Michael Shields; Writing by Luc Cohen; Editing by Bill Berkrot)

Exclusive: WHO estimates COVID-19 boosters needed yearly for most vulnerable

By Francesco Guarascio

BRUSSELS (Reuters) – The World Health Organization (WHO) forecasts that people most vulnerable to COVID-19, such as the elderly, will need to get an annual vaccine booster to be protected against variants, an internal document seen by Reuters shows.

The estimate is included in a report, which is to be discussed on Thursday at a board meeting of Gavi, a vaccine alliance that co-leads the WHO’s COVID-19 vaccine program COVAX. The forecast is subject to changes and is also paired with two other less likely scenarios.

Vaccine makers Moderna Inc and Pfizer Inc, with its German partner BioNTech, have been vocal in their view that the world will soon need booster shots to maintain high levels of immunity, but the evidence for this is still unclear.

The document shows that the WHO considers annual boosters for high-risk individuals as its “indicative” baseline scenario, and boosters every two years for the general population.

It does not say how these conclusions were reached, but shows that under the base scenario new variants would continue to emerge and vaccines would be regularly updated to meet these threats.

The U.N. agency declined to comment on the content of the internal document while Gavi did not immediately respond to a request for comment.

The document, which is dated June 8 and is still “work in progress,” also predicts under the base case that 12 billion COVID-19 vaccine doses will be produced globally next year.

That would be slightly higher than the forecast of 11 billion doses for this year cited by the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), signaling that the U.N. agency does not expect a significant ramp-up of vaccine production in 2022.

The document predicts manufacturing problems, regulatory approval issues and “transition away from some technology platforms” as potential drags on supplies next year.

It does not signal which technologies could be phased out, but the European Union, which has reserved the world’s largest volume of COVID-19 vaccines, has bet heavily on shots using messenger RNA (mRNA) technology, such as those by Pfizer and Moderna, and has forgone some purchases of viral vector vaccines from AstraZeneca and Johnson & Johnson.

WORST-CASE SCENARIO

The scenarios will be used to define the WHO’s global vaccination strategy and the forecasts may change as new data emerge on the role of boosters and the duration of vaccine protection, Gavi says in another document, also seen by Reuters.

So far about 2.5 billion doses have been administered worldwide, mostly in rich countries where over half of the population has received at least one dose, whereas in many poorer countries less than 1% has been vaccinated, according to Gavi’s estimates.

This gap could widen next year under the WHO’s most pessimistic forecast, as the need for annual boosters could push once again poorer nations to the back of the queue.

In its worst-case scenario, the U.N. agency says production would be 6 billion doses next year, due to stringent regulation for new shots and manufacturing issues with existing ones.

That could be compounded by the need for annual boosters for the entire world, and not just the most vulnerable, to combat variants and limited duration of protection.

In the more optimistic situation, all vaccines in the pipeline would get authorized and production capacity would ramp up to about 16 billion doses to meet demand. Vaccines would also be shared equitably across the world.

There would be no need for boosters as vaccines would show strong efficacy against variants and long protection.

(Reporting by Francesco Guarascio @fraguarascio; Editing by Josephine Mason and Emelia Sithole-Matarise)

Exclusive: Let down by rich and failing the poor, global vaccine scheme to be shaken up

By Francesco Guarascio

BRUSSELS (Reuters) – Shunned by rich countries and failing to meet the needs of the poorest, a program co-led by the World Health Organization (WHO) for fair distribution of COVID-19 vaccines is planning a shake-up, internal documents seen by Reuters show.

The COVAX program is far short of its target of delivering 2 billion doses by the end of the year, but does expect a big increase in supplies by early 2022, and wants to make sure that those, at least, reach the countries in direst need.

COVAX’s initial lofty ambitions to act as a clearing house for the world’s vaccines, collecting from the manufacturers in the most developed countries and quickly distributing to those in the most urgent need, have fallen flat.

So far, it has distributed a mere 90 million vaccines. While densely populated lower-income countries act as incubators for new and more dangerous strains of the coronavirus, some of the poorest countries have vaccinated less than 1% of their populations, according to estimates from Gavi, a global vaccine alliance that runs the scheme with the WHO.

The overhaul is meant to reduce COVAX’s financial risks, increase its focus on the countries most in need and reduce the participation of richer countries as both donors and recipients, according to a paper prepared by Gavi.

The document is expected to be adopted at a Gavi board meeting on Wednesday and Thursday.

“The suggestion is, subject to Board approval, to focus COVAX’s procurement efforts on all SFPs (self-financing participants) that will continue to need the facility, in such a way that enables simplified operations and reduced financial risks, based on the lessons learned over the past year,” a spokeswoman for Gavi said.

The WHO had no immediate comment, but usually lets Gavi speak about COVAX on its behalf.

CHARITY BEGINS AT HOME

Wealthy countries have generally preferred to use their financial clout to buy their own vaccines direct from the manufacturers.

And despite pleas from the WHO to share any surplus vaccines via its program, the United States, Japan and the European Union have all outlined plans to donate to countries directly, as well as to COVAX.

By prioritizing their own diplomatic and commercial interests, wealthy nations have in effect wrecked COVAX’s ambition to take overall charge of the global fight against the pandemic.

“The fact that Gavi’s board is now reviewing the way in which wealthier countries can continue to participate in the facility is in part a recognition that the set-up does not work,” said Kate Elder, senior policy adviser at the medical aid group Medecins Sans Frontieres.

About 190 countries are currently COVAX members, but one-third do not use its vaccines and only about 40 have launched their vaccination drives with jabs from COVAX, the Gavi document says.

In a separate internal document, Gavi estimates that membership may shrink to 120-130 next year.

Many rich nations are expected to step aside voluntarily, but the planned policy change will also make it costlier for middle-income countries to take part.

Whereas now Gavi takes significant financial risks in ordering vaccines on behalf of its members, next year middle-income nations that still need COVAX vaccines will have to pay for them fully in advance.

This means that countries in Latin America and the Middle East, as well as the likes of South Africa, may face higher costs and need to borrow money to secure doses.

PUTTING THE POOREST FIRST

However, the poorest countries, mostly in Africa and Southeast Asia, will keep the same conditions, with little or no costs to buy vaccines.

“The model would be redesigned with less flexible terms and conditions, aimed at simplification, and lowering financial risk to retain countries that need the facility whilst dis-incentivizing other countries from continued participation beyond the end of 2021,” one of the documents says.

And that should have tangible benefits for the poorest countries.

COVAX has raised nearly $10 billion, above its target for this year, and has begun receiving some surplus doses from rich nations. However, wealthy states’ earlier massive purchases of vaccines and curbs on exports from India, the facility’s main supplier, have left poorer countries short of supply.

Gavi believes that a projected increase in supply in the second half of the year could lift the share of those vaccinated in the poorest countries to nearly 30% by early 2022.

Gavi plans to spend $775 million to help countries distribute those vaccines and avoid repeating incidences of wastage caused by insufficient preparation and infrastructure.

With these countries facing a possible five-fold increase in the monthly throughput of vaccines, the risk of such wastage is high, one document says.

The money will be used to strengthen COVAX’s delivery system, provide better refrigeration equipment and improve healthcare systems, Gavi says.

(Reporting by Francesco Guarascio @fraguarascio; Editing by Josephine Mason)

Coronavirus wave takes Haiti, yet to begin vaccinations, by surprise

By Andre Paultre and Sarah Marsh

PORT-AU-PRINCE (Reuters) – For more than a year, Haiti escaped the worst ravages of the COVID-19 pandemic, reporting few cases and fatalities – a rare break for the poorest country in the Americas, which has so often been beset by misfortune.

COVID-19 treatment centers closed for lack of patients, Haitians resumed life as normal, and the government hesitated to even accept its allotment of free AstraZeneca vaccines through the U.N.-backed COVAX mechanism due to safety and logistical concerns.

Now, though, as some countries are already moving into a post-pandemic phase thanks to vaccination campaigns, Haiti is grappling with its first serious outbreak.

And it is one of only a handful of countries worldwide that has yet to administer a single shot of coronavirus vaccine.

Last month, infections and fatalities rose more than fivefold following the arrival of new variants, in what the Pan American Health Organization (PAHO) called a “cautionary tale in just how quickly things can change with this virus.”

Officially, Haiti had recorded 15,895 infections and 333 deaths from COVID-19 as of June 5 among its 11 million people – relatively low case numbers compared to elsewhere in Latin America and the Caribbean.

Yet data is limited due to low testing rates and doctors say the real numbers are likely much higher. Every day comes news of deaths from COVID-19 of well-known figures, like a former senator or the head of the pension agency.

And the upwards trend could prove “catastrophic,” according to Laure Adrien, General Director of Haiti’s Health Ministry.

Poor sanitation means disease can spread fast in Haiti. Its slums are densely packed, and its already overwhelmed and shambolic healthcare system is dependent on fickle donations.

Last week, two of the main hospitals treating COVID-19 patients in capital Port-au-Prince announced they were saturated.

“We are overwhelmed with patients,” said Marc Edson Augustin, medical director of St. Luke Hospital.

Jean ‘Bill’ Pape, a top Haitian infectious disease expert, said the country was now not as prepared as it had been.

“We need to reopen new centers to increase the number of dedicated COVID beds,” said Pape.

The new wave also comes amid surging gang violence that is hampering the provision of what little healthcare is available.

The St. Luke hospital warned on Monday it may have to close its COVID-19 unit altogether as violence was making it hard to stock up on oxygen at the production site in the Cite Soleil slum.

Already in February Doctors Without Borders (MSF) shut all but the emergency department at the hospital in Cite Soleil where it last year treated COVID-19 patients.

Wealthier Haitians are paying to be medevaced to Florida or the Dominican Republic.

NOT A PRIORITY

Haitian doctors largely credited their country’s apparent resilience to the coronavirus last year to its relatively young population. Around half of Haitians are under 25 years old.

Many locals dismissed the virus as not a big deal or even doubted its existence. Its importance faded amid a growing humanitarian crisis in the wake of political unrest and extreme weather associated with climate change.

So when reports emerged last month of the arrival of the new variants first identified in Britain and Brazil and an uptick in cases, reaction was initially subdued.

Authorities mandated renewed precautions like masks in public spaces, instituted an overnight curfew, and suspended year-end graduation ceremonies. President Jovenel Moise urged Haitians to drink medicinal tea to ward off the virus, an unproven remedy.

Yet many Haitians continued life as usual, with authorities unwilling or unable to enforce measures. One mayor of a Port-au-Prince district last week staged a music concert attended by thousands not wearing masks.

Pressure is building, though. PAHO Director Carissa Etienne said last week there was “no time to waste” as additional health capacity and preventive measures to curb transmission would be “decisive.”

Businesses are starting to require Haitians to only enter wearing masks and new COVID-19 treatment centers are opening.

“We have to open new structures to take more patients with respiratory difficulties to avoid a catastrophe,” said Ronald Laroche, a doctor who runs a network of low-cost health centers and hospitals, and opened a COVID-19 center this week.

On Monday, the electoral council postponed a referendum on a new constitution that had been scheduled for the end of June.

And next week, Haiti should receive its first batch – 130,000 doses – of COVID-19 vaccines through the World Health Organization’s COVAX vaccination scheme.

Doctors say the challenge now will be convincing Haitians to actually have the vaccine.

Ronald Jean, 38, a restaurant manager in Port-au-Prince, said he was for the first time afraid of the virus.

But “first the authorities should take the vaccine on television, we’ll see how they do,” he said. “And then I will decide whether or not to take it.”

(Reporting by Andre Paultre and Valerie Baeriswyl in Port-au-Prince and Sarah Marsh in Havana; Additional reporting by Anthony Boadle in Sao Paolo; Editing by Rosalba O’Brien)

Factbox: Latest on the worldwide spread of the coronavirus

(Reuters) – The head of the World Health Organization has called for launching negotiations this year on an international treaty to boost pandemic preparedness, as part of sweeping reforms envisioned by member states.

EUROPE

* Germany’s Robert Koch Institute (RKI) for infectious disease is to reduce the coronavirus risk level for the country to “high” from “very high” as the situation improves, Health Minister Jens Spahn said.

* Spain is considering easing rules on wearing face masks outdoors, as early as in mid-June.

AMERICAS

* With half the country at least partially protected against the coronavirus, Americans escaped their pandemic doldrums over the Memorial Day holiday weekend.

ASIA-PACIFIC

* South Korea closed its first phase of reservations for Johnson and Johnson vaccines as military personnel signed up for all 800,000 shots on offer, the government said.

* A shipment of coronavirus vaccines to North Korea via the global COVAX sharing program that was expected for late May has been delayed again amid protracted consultations, South Korea’s Unification Ministry said.

* Australia’s Victoria state authorities said it was still unclear whether a snap one-week lockdown to contain a fresh COVID-19 outbreak would end as planned on Thursday night, as the state grapples with a growing virus outbreak.

* Japan plans to start vaccination at workplaces and universities on June 21 to speed up the country’s inoculation drive.

MIDDLE EAST AND AFRICA

* Dubai, the second-largest member of the United Arab Emirates federation, has started offering the Pfizer-BioNTech vaccine to 12-15 year old’s, the government media office said on Twitter.

* Turkey further eased measures including partially lifting a weekend lockdown and opening restaurants to a limited number of guests.

MEDICAL DEVELOPMENTS

* A Wuhan-based affiliate of China’s Sinopharm said the start of operations at a new factory will raise the annual production capacity of its COVID-19 vaccine to at least 1 billion doses.

* A deal on an intellectual property waiver for COVID-19 vaccines at the World Trade Organization was no closer to acceptance on Monday despite Washington’s backing, due to expected skepticism about a new draft, sources close to the talks told Reuters.

ECONOMIC IMPACT

* Global stocks again hit record highs and oil rose on Tuesday, before European and U.S. data that should this week offer major clues to the health of the world economy.

* Euro zone manufacturing activity expanded at a record pace in May, according to a survey which suggested growth would have been even faster without supply bottlenecks that have led to an unprecedented rise in input costs.

* Ireland will begin to gradually phase out temporary coronavirus-related jobless payments later this year while maintaining other income and business supports as the economy fully reopens, Public Expenditure Minister Michael McGrath said.

* Turkish factory activity shrank in May for the first time in a year as output and new orders slowed down due to a 17-day full lockdown imposed to curb a surge in new coronavirus cases, a survey showed.

(Compiled by Jagoda Darlak and Ramakrishnan M.; Editing by William Maclean)

COVID fight could return ‘to square one’: experts sound vaccines alarm

By Kate Kelland

LONDON (Reuters) – India’s export ban on COVID-19 shots risks dragging the battle against the pandemic “back to square one” unless wealthy nations step in to plug a gaping hole in the COVAX global vaccine-sharing scheme, health specialists said on Thursday.

COVAX, which is critical for poorer countries, relies on AstraZeneca shots made by the Serum Institute of India, the world’s biggest maker of vaccines. It was already around 100 million doses short of where it had planned to be when India halted exports a month ago amid a surge in infections there.

Rich countries with plentiful COVID-19 vaccine stocks must now share them immediately, at scale, the global experts said, otherwise the pandemic could be prolonged as the world struggles to contain a virus that is continuing to spread and mutate.

“It is a huge concern,” said Anna Marriott, health policy manager at the global charity Oxfam. She and others said it was imperative that wealthy countries and regions make good on their rhetoric and share excess vaccines now.

“The current approach that relies on a few pharma monopolies and a trickle of charity through COVAX is failing – and people are dying as a result.”

Reuters reported on Tuesday that India is extending its ban, meaning it is now unlikely to resume major exports before October.

Will Hall, global policy manager for the Wellcome global health trust, said COVAX’s heavy reliance on the Serum Institute left it vulnerable. India’s extension of its export ban made it even more crucial for rich countries to share doses via the scheme, he said, “not in six months’ time, not in a month’s time, but now”.

“We’re not going to beat this virus unless we think and act globally,” he added. “We all should be concerned about this – the more the virus continues to spread, the greater the risk of it mutating to a stage where our vaccines and treatments no longer work. If that happens we’re back to square one.”

A highly transmissible new variant of the novel coronavirus first identified in India has spread to several countries around the world.

‘VERY FEW OPTIONS’

COVAX aims to get vaccines to at least 20% of the populations of the more-than 90 low and middle-income countries signed up to receive the shots as donations. It has so far distributed about 65 million doses of mainly the AstraZeneca COVID-19 vaccine, many of them to Africa.

A spokeswoman for the GAVI vaccines alliance, which co-leads COVAX, said the facility was working hard to make up supplies.

“We’re trying to find different ways of making sure that those countries that have received the first dose are able to also receive a second dose and that vaccinations can continue,” she told Reuters. “What we need right now, to meet the immediate needs, is dose sharing.”

The United States said on Wednesday it would share a total of 20 million doses of Pfizer’s, Moderna’s and Johnson & Johnson’s vaccines by the end of June, donating a significant amount via COVAX, on top of 60 million AstraZeneca shots it had already planned to give to other countries.

EU trade commissioner Valdis Dombrovskis said this week that the bloc was working to significantly ramp up vaccine donations through COVAX in the second half of 2021. Vaccine sharing announced by EU member states has so far amounted to 11.1 million vaccines, he said, of which 9 million are being shared via COVAX.

Britain, meanwhile, will have enough surplus doses to fully vaccinate at least 50 million people in poorer countries once every adult at home has been fully vaccinated, according to analysis by UNICEF’s UK office last week.

The GAVI spokeswoman said COVAX’S reliance on the Serum Institute was based, largely, on its vast production capacity, ability to deliver at low cost and on assurances that it would be able to produce the millions of doses needed at speed.

“It always was COVAX’s plan to grow and diversify its portfolio to 10-12 vaccines but at the start of the year when approved vaccines were only slowly coming online, we had very few options available to us,” she said.

(Reporting by Kate Kelland; Additional reporting by Francesco Guarascio in Brussels and Ludwig Burger in Frankfurt; Editing by Pravin Char)

India’s halt to vaccine exports ‘very problematic’ for Africa

By Giulia Paravicini

ADDIS ABABA (Reuters) – An extended halt to exports of COVID-19 vaccines from India, where authorities are battling a wave of domestic infections, risks derailing vaccination efforts already underway in Africa, one of the continent’s top health officials said on Tuesday.

India stopped vaccine exports a month ago and, according to a Reuters report earlier on Tuesday, is now unlikely to resume major exports before October, dealing a major setback to the global COVAX initiative on which many poor countries rely.

Africa has lagged far behind other regions due to supply issues and meagre financial resources but had planned to vaccinate 30-35% of its population by the end of the year and 60% within the next two to three years.

“This is very problematic as it means unpredictability of our vaccination programs and a serious risk of not achieving our stated target… on time,” the director of the Africa Centers for Disease Control and Prevention, John Nkengasong, wrote to Reuters.

Those targets primarily relied on supplies from the global COVAX vaccine-sharing facility, which has depended heavily on AstraZeneca shots produced by the Serum Institute of India (SII).

“Given India’s huge challenges, it will be impossible to expect anything soon,” Nkengasong said.

There have been at least 4,742,000 reported infections and 126,000 reported deaths caused by the novel coronavirus in Africa so far, according to a Reuters tally.

And while the pandemic’s impact has been less acute than in the United States, Europe and now India, Africa’s largely unvaccinated population of over 1 billion remains vulnerable, experts say.

COVAX had already begun distributing millions of doses of the two-shot AstraZeneca vaccine to countries across Africa. But those initial shipments have now been largely exhausted, with around 80% having been administered as a first dose, according to the World Health Organization (WHO).

Most countries using COVAX will now surpass the 12-week maximum interval recommended between the first and second dose of AstraZeneca unless 20 million doses are delivered by the end of June and another 5 million in July, the WHO said.

“The supply gap could be closed if countries with adequate supplies set aside a percentage of vaccines for COVAX,” said Richard Mihigo, coordinator of the WHO’s Immunization and Vaccines Development Program in Africa.

A deal negotiated with Johnson & Johnson by the African Union should supply Africa with 400 million vaccine doses beginning in the third quarter of this year.

Several countries’ health officials told Reuters they had yet to receive updated information on expected arrival dates for COVAX shots. Some are now weighing their options.

Ethiopia, for example, has received just 2.2 million of the 7.6 million AstraZeneca shots it was due to get through COVAX by the end of April.

“We were expecting some delays, but not to this scale. As a country we must search other options,” Muluken Yohannes, a senior adviser to Ethiopia’s health ministry, told Reuters.

(Additional reporting by Omar Mohammed in Nairobi, Christophe Van Der Perre in Dakar and Camillus Eboh and Felix Onuah in Abuja; Editing by Joe Bavier and Alexandra Hudson)

WHO urges rich countries to donate shots instead of vaccinating children

GENEVA (Reuters) – The World Health Organization urged rich countries on Friday to reconsider plans to vaccinate children and instead donate COVID-19 shots to the COVAX scheme for poorer countries.

WHO chief Tedros Adhanom Ghebreyesus also said the second year of the pandemic was set to be more deadly than the first, with India a huge concern.

“I understand why some countries want to vaccinate their children and adolescents, but right now I urge them to reconsider and to instead donate vaccines to #COVAX,” he told a virtual meeting in Geneva.

Indian Prime Minister Narendra Modi sounded the alarm over the rapid spread of the coronavirus through India’s vast countryside on Friday, as the country’s official tally of infections crossed 24 million and over 4,000 people died for the third straight day.

More than 160.71 million people have been reported to be infected by the coronavirus globally and 3,477,379​ have died, according to a Reuters tally.

Infections have been reported in more than 210 countries and territories since the first cases were identified in China in December 2019.

(Reporting by Emma Farge in Geneva and Michael Shields and John Miller in Zurich; Writing by Nick Macfie; Editing by Catherine Evans)